Drugs / FTC/TDF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04652700 Comparator | Mar 2021 → Aug 2023 | — | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTC/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652700 ↗ |
| Route | Oral | “Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months” NCT04652700 ↗ |